MIR

EX-99.1

2 a2026-10x27exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Third Quarter 2026 Financial Results

•Revenues for the third quarter increased 24.5% to $277.8 million, compared to $223.1 million in the same period in 2025.

•GAAP net income was $7.8 million in the third quarter, a 151.6% increase compared to GAAP net income of $3.1 million in the same period in 2025; Adjusted EBITDA was $64.8 million in the third quarter, a 23.7% increase from $52.4 million in the same period last year.

•GAAP net earnings per share in the third quarter was $0.03, compared to $0.01 in the same period in 2025. Adjusted earnings per share for the quarter was $0.12, compared to $0.12 in the same period in 2025. The current period calculation of Adjusted EPS includes stock based compensation expense.

•Third quarter orders, excluding the acquisitions of Paragon and the July results of Certrec, were $340 million, a 62% increase from $209 million in the same period last year. Including the acquisitions of Paragon and the July results of Certrec, third quarter orders were $386 million, a 85% increase compared to the same period last year.

•The company revised 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

Atlanta, GA – October 27, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the third quarter ended September 30, 2026.

“Third quarter results showcase quarterly orders performance, an inflection in organic revenue growth, and a doubling of year-to-date adjusted free cash flow generation,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Orders continued to trend higher, up 62% excluding acquisitions, boosted by a 105% increase in nuclear power-related orders. Organic revenue increased 6.5% in the third quarter and we expect mid-to-high teens growth in the fourth quarter. Meanwhile, adjusted free cash flow totaled $47 million in the quarter, or $107 million year-to-date. We expect to reduce net leverage to approximately 2.6x by year-end, reflecting continued strong adjusted free cash flow.”

Logan continued, “Our business is benefiting from today’s reinvestment in the existing nuclear reactor fleet. Mirion has a presence in over 98% of commercial nuclear power plants globally and approximately 80% of our nuclear power-related revenue comes from reactors operating today. Meanwhile, we continue to capture additional opportunities from large-scale new builds and small modular reactors.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We are updating our guidance to reflect increased visibility to full year performance.”

Mirion revised 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

•Revenue growth of approximately 24% – 25%; includes foreign exchange rate and acquisition-related impacts (previously 22.0% – 24.0%).

•Organic Revenue growth of approximately 7% – 8% (previously 5.0% – 7.0%).

•Adjusted EBITDA of approximately $285 million – $292 million; Adjusted EBITDA margin of approximately 24.7% – 25.2% (previously $285 million – $300 million and 25.0% - 26.0%, respectively).

•Adjusted Free Cash Flow of approximately $170 million – $185 million; Adjusted Free Cash Flow Conversion of approximately 60% – 63% of Adjusted EBITDA (previously $155 million - $175 million and 54% - 58%, respectively).

•Adjusted EPS of approximately $0.50 – $0.54 per share (previously $0.48 - $0.55 per share).

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free Cash Flow and Adjusted Free Cash Flow conversion are not available without unreasonable effort.

Exhibit 99.1

N

EX-99.1

2 a2026-07x28exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces Second Quarter 2026 Financial Results

•Revenues for the second quarter increased 19.7% to $266.8 million, compared to $222.9 million in the same period in 2025.

•GAAP net income was $8.1 million in the second quarter, a 4.7% decrease compared to GAAP net income of $8.5 million in the same period in 2025; Adjusted EBITDA was $65.3 million in the second quarter, a 27.5% increase from $51.2 million in the same period last year.

•GAAP net earnings per share in the second quarter was $0.03, compared to $0.04 in the same period in 2025. Adjusted earnings per share for the quarter was $0.12, compared to $0.11 in the same period in 2025. The current period calculation of Adjusted EPS includes stock based compensation expense.

•Second quarter orders, excluding Paragon & Certrec acquisitions, were $229 million, a 10% increase from $208 million in the same period last year. Including Paragon and Certrec acquisitions, second quarter orders were $291 million, a 40% increase compared to the same period last year.

•The company reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

Atlanta, GA – July 28, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the second quarter ended June 30, 2026.

“Our second quarter performance reflects margin expansion across both operating segments, increased adjusted free cash flow, and continued orders and backlog growth,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “We captured several large opportunity orders in the second quarter with substantial opportunity available for the rest of the year.”

Logan continued, “Our acquisitions of Certrec and Paragon have augmented our ability to capitalize on growing nuclear power opportunities in North America. Moreover, our global presence puts us at the forefront of international nuclear growth ambitions.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We remain well-positioned for second half 2026 accelerated revenue growth, adjusted free cash flow, and margin expansion. We are maintaining our full year 2026 guidance while adjusting the end-market composition of our Medical segment.”

Mirion reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, Adjusted Free Cash Flow, and Adjusted EPS guidance for the fiscal year ending December 31, 2026.

•Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.

•Organic Revenue growth of approximately 5.0% – 7.0%.

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%.

•Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA.

•Adjusted EPS of approximately $0.48 – $0.55 per share.

Exhibit 99.1

News Release

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free Cash Flow and Adjusted Free Cash Flow conversion are not available without unreasonable effort.

Conference Call

Mirion will host a conference call tomorrow, July 29, 2026 at 10:00 a.m. ET to discuss its financial results. Participants may access the call by dialing 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call. A live webcast will also be available at https://ir.mirion.com/news-events.

A telephonic replay will be available shortly after the conclusion of the call and until August 12, 2026. Participants may access the replay at 1-844-512-2921 or 1-412-317-6671, and enter access code 13761513. An a

EX-99.1

2 a2026-04x28exhibit991.htm

EX-99.1

Document

Exhibit 99.1

News Release

Mirion Announces First Quarter 2026 Financial Results

•Revenues for the first quarter increased 27.5% to $257.6 million, compared to $202.0 million in the same period in 2025.

•GAAP net loss was $3.4 million in the first quarter, compared to GAAP net income of $0.4 million in the same period in 2025; Adjusted EBITDA was $54.3 million in the first quarter, a 16.3% increase from $46.7 million in the same period last year.

•GAAP net loss per share in the first quarter was $0.01, compared to a GAAP net earnings per share of $0.00 in the same period in 2025. Adjusted earnings per share for the quarter was $0.10, compared to $0.10 in the same period in 2025. The calculation for adjusted earnings per share has been adjusted for the current period to include stock-based compensation.

•First quarter orders, excluding Paragon & Certrec acquisitions, were $241 million, a 19% increase from $203 million in the same period last year. Including Paragon and Certrec acquisitions, first quarter orders were $288 million, a 42% increase compared to the same period last year.

•The company reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance for the fiscal year ending December 31, 2026, while revising Adjusted EPS guidance to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

Atlanta, GA – April 28, 2026 – Mirion (“we” or the “company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets, today announced results for the first quarter ended March 31, 2026.

“Our first quarter performance showcased substantial orders growth led by nuclear power demand and as-expected Adjusted EBITDA performance and margins,” commented Mirion’s Chairman and Chief Executive Officer Thomas Logan. “Record capital spending commitments by power plant operators are driving accelerating momentum in the sector, which is translating into significant Nuclear Power demand.”

Logan continued, “Our strong performance also reflects Paragon’s contributions in its first full quarter with Mirion. Paragon is the ‘tip of the spear’ for growing installed base dynamics. Integration is on-pace, and we are already realizing commercial synergies.”

2026 Guidance

Commenting on Mirion’s full year 2026 guidance, Logan said, “We remain on track for 2026 revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance. Our business continues to capture momentum in Nuclear Power and Cancer Care markets. Additionally, we are bringing new products to market and enhancing our current offerings to meet customers where they are headed.”

Mirion reaffirmed 2026 total revenue growth, Organic Revenue growth, Adjusted EBITDA, and Adjusted Free Cash Flow guidance for the fiscal year ending December 31, 2026, while revising Adjusted EPS guidance to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

•Revenue growth of approximately 22.0% – 24.0%; includes foreign exchange rate and acquisition-related tailwinds.

•Organic Revenue growth of approximately 5.0% – 7.0%.

•Adjusted EBITDA and Adjusted EBITDA margin of approximately $285 million – $300 million; Adjusted EBITDA margin of approximately 25.0% – 26.0%.

Exhibit 99.1

News Release

•Adjusted Free Cash Flow of approximately $155 million – $175 million; Adjusted Free Cash Flow Conversion of approximately 54% – 58% of Adjusted EBITDA.

•Adjusted EPS of approximately $0.48 – $0.55 per share (previously $0.50 – $0.57 per share); adjusted to reflect the impact of a special one-time CEO retention grant of performance vesting stock options disclosed on April 13, 2026.

Additional modeling and guidance assumptions are included in the appendix of the earnings presentation on the Company’s investor relations page.

The Company’s guidance contains forward-looking statements and actual results may differ materially as a result of known and unknown uncertainties and risks, including those set forth below under the heading “Forward-Looking Statements.” In addition, forward-looking non-GAAP financial measures are presented on a non-GAAP basis without reconciliations of such forward-looking non-GAAP measures due to the inherent difficulty in projecting and quantifying the various adjusting items necessary for such reconciliations, such as stock-based compensation expense, amortization and depreciation expense, merger and acquisition activity and purchase accounting adjustments, that have not yet occurred, are out of Mirion’s control, or cannot be reasonably predicted. Accordingly, reconciliations of our guidance for Organic Revenue growth, Adjusted EBITDA, Adjusted EBITDA margin, Adjusted EPS, Adjusted Free C